Sugi Predict

Sugi Predict / Targets / MAPK11

MAPK11

Mitogen-activated protein kinase 11 · Q15759 · MAPK11 on Sugi Atlas →

107,017 patent compounds predicted against MAPK11, 70,802 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL185300 SCHEMBL185300 1.00 20/20
SCHEMBL239606 SCHEMBL239606 0.67 20/20
SCHEMBL245150 SCHEMBL245150 0.64 20/20
SCHEMBL242628 SCHEMBL242628 0.63 20/20
SCHEMBL244356 SCHEMBL244356 0.63 20/20
SCHEMBL242687 SCHEMBL242687 0.59 20/20
SCHEMBL242584 SCHEMBL242584 0.58 20/20
SCHEMBL240712 SCHEMBL240712 0.51 20/20
SCHEMBL243632 SCHEMBL243632 0.50 20/20
SCHEMBL67984 SCHEMBL67984 0.89 19/20
SCHEMBL243751 SCHEMBL243751 0.70 19/20
SCHEMBL240047 SCHEMBL240047 0.64 19/20
SCHEMBL244085 SCHEMBL244085 0.61 19/20
SCHEMBL70674 SCHEMBL70674 0.60 19/20
SCHEMBL243562 SCHEMBL243562 0.60 19/20
SCHEMBL241726 SCHEMBL241726 0.55 19/20
SCHEMBL240807 SCHEMBL240807 0.52 19/20
SCHEMBL243691 SCHEMBL243691 0.51 19/20
SCHEMBL68380 SCHEMBL68380 0.75 18/20
SCHEMBL69565 SCHEMBL69565 0.68 18/20

Clinical trials — most relevant to MAPK11 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Mechanism of Sorafenib Resistance in Patients With Advanced Hepatocellular Carcinoma PHASE4UNKNOWN
Treatment With HMG-COA Reductase Inhibitor of Growth and Bone Abnormalities in Children With Noonan Syndrome PHASE3COMPLETED
Trametinib in Treating Patients With Recurrent or Progressive Low-Grade Ovarian Cancer or Peritoneal Cavity Cancer PHASE2/PHASE3COMPLETED
A Phase 1B/2A Trial of Combination of ASTX727 With ASTX029 in Acute Myeloid Leukemia PHASE1/PHASE2WITHDRAWN
A Study to Investigate the Novel Agent BNT111 and Cemiplimab in Combination or as Single Agents in Patients With Advanced Melanoma That Has Not Responded to Other Forms of Treatment PHASE2COMPLETED
Binimetinib and Encorafenib for the Treatment of Advanced Solid Tumors With Non-V600E BRAF Mutations PHASE2ACTIVE_NOT_RECRUITING
HEM iSMART-D: Trametinib + Dexamethasone + Chemotherapy in Children With Relapsed or Refractory Hematological Malignancies PHASE1/PHASE2RECRUITING
A Study to Evaluate RAF265, an Oral Drug Administered to Subjects With Locally Advanced or Metastatic Melanoma PHASE1/PHASE2COMPLETED
To Evaluate the Efficacy Beyond Progression of Vemurafenib+Cobimetinib Associated With Local Treatment Compared to Second-line Treatment in Patients With BRAFV600+ Metastatic Melanoma in Focal Progression With First-line+Vemurafenib+Cobimetinib. PHASE2UNKNOWN
Neoadjuvant Dabrafenib, Trametinib and/or Pembrolizumab in BRAF Mutant Resectable Stage III Melanoma PHASE2UNKNOWN
A Trial of Targeted Therapies for Patients With Slow-Flow or Fast-Flow Vascular Malformations PHASE2RECRUITING
Cediranib Maleate in Treating Patients With Recurrent or Persistent Endometrial Cancer PHASE2COMPLETED
Perifosine in Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma PHASE2COMPLETED
HDAC Inhibitor Vorinostat in Resistant BRAF V600 Mutated Advanced Melanoma PHASE1/PHASE2COMPLETED
Bevacizumab and Erlotinib in Treating Patients With Advanced Liver Cancer PHASE2COMPLETED
Study of ASTX029 in Subjects With Advanced Solid Tumors PHASE1/PHASE2COMPLETED
A Study to Investigate Fadraciclib (CYC065), in Subjects With Leukemia or Myelodysplastic Syndrome (MDS) PHASE1/PHASE2SUSPENDED
Combination Therapy (Mirdametinib and Sirolimus) for RAS Mutated Relapsed Refractory Multiple Myeloma PHASE1/PHASE2SUSPENDED
A Study to Look at the Electrical Activity of the Heart in Subjects With Solid Tumor Cancers, Before and After Receiving the Study Treatment, GSK1120212 PHASE1COMPLETED
BEP Study Phase I (Bevacizumab, Everolimus, Panitumumab) PHASE1COMPLETED
A Study to Test Different Doses of BI 1823911 Alone and Combined With Other Medicines in People With Different Types of Advanced Cancer With KRAS Mutation PHASE1ACTIVE_NOT_RECRUITING
Uncovering Genes Behind Cartilage Tumors and Vascular Anomalies Using Genomic Sequencing nanRECRUITING
Clinical, Genetic, and Epidemiologic Study of Children and Adults With RASopathies nanRECRUITING
Evaluation of Human Melanocytes After the Use of PRP Versus Fractional CO2 Laser in Vitiligo nanUNKNOWN
RASopathy Biorepository nanRECRUITING
Clinical Genetics Branch Eligibility Screening Survey nanNOT_YET_RECRUITING
Targeted Treatment Plus Tislelizumab and HAIC for Advanced CRCLM Failed From Standard Systemic Treatment nanACTIVE_NOT_RECRUITING
BRAF-/MEK-Inhibition With Dabrafenib and Trametinib in Melanoma Patients nanCOMPLETED
Biomarkers in Samples From Patients With Endometrial Cancer nanWITHDRAWN
Acceptance and Commitment Therapy for Caregivers of Children With a RASopathy: An Internal Pilot Feasibility Study and Follow-up Randomized Controlled Trial nanRECRUITING

Related proteins — ESM-2 sequence neighbours (a MAPK11 binder may also engage these)

ProteinNameSimilarity
Q9WUI1 — 1.000 Q9WUI1 →
P70618 — 0.997 P70618 →
MAPK14 Mitogen-activated protein kinase 14 0.996 landscape →
P47811 — 0.993 P47811 →
O02812 — 0.992 O02812 →
O62618 — 0.992 O62618 →
O61443 — 0.991 O61443 →
Q9DGE1 — 0.991 Q9DGE1 →
Q38HL5 — 0.990 Q38HL5 →
Q2U469 — 0.990 Q2U469 →
O08911 — 0.989 O08911 →
MAPK13 Mitogen-activated protein kinase 13 0.989 landscape →
A2QRF6 — 0.988 A2QRF6 →
A0A5B9GBF0 — 0.988 A0A5B9GBF0 →
Q63538 — 0.988 Q63538 →
Q0D0P5 — 0.988 Q0D0P5 →
A3EZ55 — 0.988 A3EZ55 →
Q9Z1B7 — 0.988 Q9Z1B7 →
Q8NJT7 — 0.988 Q8NJT7 →
Q1DUU8 — 0.988 Q1DUU8 →
P47812 — 0.988 P47812 →
Q9I958 — 0.988 Q9I958 →
Q4WSF6 — 0.987 Q4WSF6 →
Q9P419 — 0.987 Q9P419 →
A1IVT7 — 0.987 A1IVT7 →
Q90336 — 0.987 Q90336 →
P0CP69 — 0.987 P0CP69 →
Q84UI5 — 0.986 Q84UI5 →
Q0U4L8 — 0.986 Q0U4L8 →
Q5I6M2 — 0.986 Q5I6M2 →